Many elements of immune system activation are linked with depression – indeed, immuno-metabolic dysregulation is seen in 20–30% of people with MDD. People with immuno-metabolic dysregulation in MDD are at risk of comorbidities and appear to respond less well to traditional antidepressants.1

Interoceptive signals provide the brain with information on the balance between energy supply and demand, and the brain responds by triggering appropriate physiological and behavioural reactions intended to save energy or increase energy intake.1 Various factors, including genetic predisposition or environmental challenges (e.g., excessive nutritional intake or stress/trauma) can disrupt this internal homeostasis.1 For example, increased levels of inflammatory markers may result in central insulin or leptin resistance, with the brain misreading interoceptive signals regarding body energy status, and triggering excessive energy-saving or calorie intake-increasing responses, such as increased appetite coupled with reduced activity.1 These may further exacerbate the dysregulation (e.g., further increase in inflammatory signalling), creating a self-sustaining detrimental cycle.1

file_download Download in HQ

Related content

description Article
Treatment-Resistant Depression (TRD) – definition, clinical manifestation, and evidence-based treatment

Treatment-resistant depression (TRD) represents a significant clinical challenge, affecting approximately 30% of individuals with major depressive disorder (MDD) who fail to respond to at least two adequate antidepressant trials.

25.09.2025 Depression
image Image Diagram titled 'Sequential Treatment Optimization Scheme for MDD' showing patient improvement over treatment time across four stages. Stage 1 includes monotherapy, dose optimization, and rTMS; Stage 2 includes augmentation, combination antidepressant, add-on treatment, rTMS/ECT; Stage 3 includes add-on psychopharmacotherapy, switch to tranylcypromine, rTMS/TBS/ECT/VNS; Stage 4 includes repetition or experimental psychopharmacotherapy/brain stimulation. Curved lines represent different patient trajectories, with horizontal dotted lines indicating thresholds for response and remission. Some lines show improvement, while others show little or worsening response over time.
Sequental Treatment Optimization Scheme for Major Depressive Disorder

Sequential treatment optimization scheme for major depressive disorder generated according to international evidence.

18.09.2025 Depression
image Image Infographic titled 'Identification and Effective Management of Factors Potentially Confounding Treatment Response'. It shows eight stacked boxes listing key steps: Check dose and duration of the current antidepressant trial Explore and reduce side effects Consider and treat comorbidities Consider and reduce ongoing stressors Evaluate treatment adherence Pharmacogenomic testing (CYP450) Check and avoid unfavorable medical interaction Evaluate initial therapies and follow recommended treatment algorithm. At the bottom, references are cited (Dold & Kasper, 2017; Kraus et al., 2019), and the image is credited to Neurotorium."
Identification and effective management of factors potentially confounding treatment response

Key steps for managing factors that may confound antidepressant treatment response, including dose, side effects, comorbidities, stressors, adherence, pharmacogenomics, interactions, and treatment algorithms.

18.09.2025 Depression